The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 04, 2026

Filed:

Apr. 26, 2021
Applicant:

Vanderbilt University, Nashville, TN (US);

Inventors:

Richard T. O'neil, Nashville, TN (US);

Matthew H. Wilson, Nashville, TN (US);

Assignee:

Vanderbilt University, Nashville, TN (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 5/0783 (2010.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); C12N 15/90 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0636 (2013.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); C12N 15/907 (2013.01); A61K 2239/31 (2023.05); A61K 2239/55 (2023.05); C12N 2510/00 (2013.01);
Abstract

Disclosed herein are engineered cell-based peptide delivery platforms based on T cells lacking Perforin function. Perforin-null T cells lack cytotoxic effector function and thus are not capable of killing target cells by conventional Perforin dependent pathways. However, they efficiently home to target tissues where they can invade, persist, and proliferate. The homing ability of perforin lacking T cells can therefore be used to deliver anti-cancer or pre-immune peptides to tumors, or therapeutic peptides to other target tissues based on antigen recognition. Because the cells lack cytotoxic effector function due to loss, knockdown, or inhibition of Perforin, they can be targeted to tissues based on antigen recognition without destroying the target tissue directly.


Find Patent Forward Citations

Loading…